Tango Therapeutics Inc - Asset Resilience Ratio
Tango Therapeutics Inc (TNGX) has an Asset Resilience Ratio of 57.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Tango Therapeutics Inc assets under control for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Tango Therapeutics Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Tango Therapeutics Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tango Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tango Therapeutics Inc (TNGX) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $230.86 Million | 57.9% |
| Total Liquid Assets | $230.86 Million | 57.90% |
Asset Resilience Insights
- Very High Liquidity: Tango Therapeutics Inc maintains exceptional liquid asset reserves at 57.90% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tango Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Tango Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Tango Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Tango Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.90% | $230.86 Million | $398.69 Million | -1.62pp |
| 2024-12-31 | 59.52% | $188.39 Million | $316.49 Million | -7.67pp |
| 2023-12-31 | 67.19% | $270.50 Million | $402.57 Million | -2.95pp |
| 2022-12-31 | 70.15% | $306.17 Million | $436.47 Million | +1.66pp |
| 2021-12-31 | 68.48% | $342.51 Million | $500.15 Million | -9.66pp |
| 2020-12-31 | 78.14% | $161.94 Million | $207.25 Million | +46.69pp |
| 2019-12-31 | 31.45% | $17.54 Million | $55.76 Million | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more